同步纯化人心肌肌钙蛋白T、I

同步纯化人心肌肌钙蛋白Ｔ、Ｉ李志梁付朝平钱学贤陆青王素华黎梅兰（第一军医大学珠江医院心内科,广州５１０２８２）关键词心肌肌钙蛋白Ｔ;心肌肌钙蛋白Ｉ;同步纯化收稿日期：１９９６－０４－１７;接受日期：１９９６－０８－２７。心肌肌钙蛋白包括３种不同的蛋白...     

肌钙蛋白I和肌红蛋白在急性心肌梗死患者血清中的变化特点及其诊断价值

目的:探讨肌钙蛋白I、CKMB的即时检测技术在急诊科心肌梗死患者中的应用及其临床意义。方法:研究对象为2012年10月至2013年8月于我急诊科急诊的急性心肌梗死患者,按就诊时间分为对照组和实验组。对照组患者采用常规化验室检测肌钙蛋白I、CKMB,实验组采用急诊科即时检测方法检测肌钙蛋白I、CKMB。对比两组患者从就诊到确诊的时间、住院天数、治愈率、心功能不全发生率和死亡率。结果:实验组患者的确诊时间为(25.5±5.6)min,住院天数为(9.89±1.5)天,治愈率为80.8%,心功能不全发生率为15.4%。对照组患者的确诊时间为(66.8±10.0)min,住院天数为(12.6±2.5)天,治愈率为56.0%,心功能不全发生率为32.0%P均.0.05,有统计学意义。两组患者死亡率分别为12%和3.8%,无明显差异。结论:对心肌梗死患者采用肌钙蛋白I、CKMB的即时检测对于提高患者治愈率,减少确诊时间和住院时间,降低心功能不全发生率有很大帮助。     

多孔硅Bragg反射镜适配子生物传感器检测心肌肌钙蛋白I

通过脉冲腐蚀法制备多孔硅Bragg反射镜,将心肌肌钙蛋白I（cTnI）适配子共价固定到多孔硅Bragg反射镜的孔洞中,发现适配子能与cTnI分子特异性结合。定量分析不同浓度的cTnI与适配子结合后多孔硅Bragg反射镜的反射谱峰位的红移情况。结果表明：基于多孔硅Bragg反射镜适配子生物传感器的光学检测具有良好的特异性,且具有免标记及检测时间短等优异性能。传感器的线性检测范围0．05-4nmol／L,最低检测限为0．05nmol／L。     

肌钙蛋白I水平检测对急诊房颤患者的临床意义

目的:探讨房颤患者急诊入院时检测肌钙蛋白I(Tn I)水平的临床作用及预测价值。方法:回顾性分析我院523例房颤患者的临床资料,将资料中数据进行统计学分析处理。患者分为三组:1组患者Tn I轻度升高;2组患者Tn I正常;3组患者未检测Tn I,分别就三组患者的基线特征以及就诊时的症状展开数据比较,并且单变量及多变量分析Tn I升高的预测因子。设置主要终点为1年内所有原因导致的死亡及心肌梗死(MI),患者从入院时起随访1年,记录期间的MI发生情况及死亡情况。结果:173例患者(33%)Tn I轻度升高(均值0.56 ng/m L),225例患者(43%)Tn I正常,125例患者(24%)未检测Tn I。住院期间1组患者(50%)的心功能检查异常明显高于组2和组3(28%和29%,P≤0.001),1组患者(22%)主要终点发生率明显高于2组(10%)和3组患者(15%)(P=0.002),有统计学意义。结论:肌钙蛋白I轻度升高与冠脉疾病(CAD)发生率增加及MI发生率增加有关,但对于总体死亡率无影响。     

心肌坏死标志物联合检测对急性心肌梗死早期诊断及鉴别的价值

目的:探讨心肌坏死标志物联合检测在急性心肌梗死早期诊断及鉴别中的意义。方法:选取2010年12月至2013年5月我院收治的90例患者,45例确诊急性心肌梗死患者为观察组,其余45例非急性心肌梗死患者为对照组。分别采集两组患者静脉血4 m L用于检验。采用免疫抑制法测定患者血清中肌酸激酶(CK)和肌酸激酶同工酶(CK-MB)含量,采用电化学发光法检测肌钙蛋白I(c Tn I)和肌红蛋白(MYO)含量。观察并比较不同时间点两组患者血清中CK、CK-MB、c TnⅠ及MYO含量的变化情况。结果:与对照组比较,观察组的血清CK、CK-MB、c TnⅠ及MYO的含量明显升高,其中CK及MYO升高最为显著,差异具有统计学意义(P0.05)。CK、CK-MB在发病3~6 h后快速升高,24 h达高峰;c TnⅠ前24 h与CK-MB同步,但维持时间较长;MYO在发病后1~2 h发生异常,12 h达峰值(P0.05)。结论:心肌坏死标志物联合检测可提高急性心肌梗死的检出率,有助于疾病的及时发现、诊断和治疗。     

蝮蛇咬伤患者肌酸激酶和肌钙蛋白I的变化与心功能相关性研究

目的 探讨蝮蛇咬伤患者心肌酶学(CK-MB、CK)和肌钙蛋白I(cTnI)变化与心功能的相关性.方法 将106例蝮蛇咬伤患者按病情程度分为轻、重、危重型3组,对3组患者的心肌肌钙蛋白I及心肌酶学、左室Tei指数进行测定并进行比较分析.结果 危重型组患者的CK、CK-MB、Tei指数、cTnI阳性率均高于轻、重型组,差异有显著性(P<0.05).cTnI呈阳性患者的左室Tei指数与CK、CK-MB相关系数为0.311、0.266.结论 cTnI对蝮蛇咬伤患者心肌损伤的敏感性及特异性均高于CK和CK-MB.蝮蛇咬伤中毒患者心肌酶学升高可以判断骨髂肌损伤程度,只有极少数危型蝮蛇咬伤患者合并有心肌损伤,左室Tei指数测定也证实蝮蛇咬伤cTnI呈阳性者均有心功能受损.     

心肌肌钙蛋白I和糖原磷酸化酶同工酶BB金标记免疫层析联合检测法的建立

目的：建立人心肌肌钙蛋白I（cTnI）及糖原磷酸化酶同工酶BB（GPBB）的胶体金免疫层析联合检测法。方法：以纯化的人心肌cTnI和GPBB为免疫原免疫小鼠,制备抗cTnI和抗GPBB单克隆抗体,并用胶体金标记cTnI和GPBB抗体,采用免疫层析技术建立快速准确检测cTnI和GPBB的胶体金免疫层析法。结果：建立的检测方法灵敏度高,可检出血液样品中1ng／mL的cTnI和7ng／mL的GPBB;特异性强,与心肌肌钙蛋白T、心肌肌钙蛋白C、肌酸激酶同工酶均无交叉反应。结论：该方法特异性强,灵敏度高,快速、简便,弥补了传统心肌梗死诊断方法的不足,对急性心肌梗死的早期筛查有重要意义,具有较高的临床应用价值和广泛的应用前景。     

心肌肌钙蛋白Ⅰ临床应用进展

心肌肌钙蛋白I(Cardiac Troponin I,cTnI)作为诊断心肌损伤的血清标志物之一,同其它检测指标相比,具有出现时间早、诊断窗口期宽、特异性强、诊断阈值明确及检测快速等优点。由于心肌肌钙蛋白I为心肌细胞所特有,因此在心肌缺血性损伤、心肌非缺血性损害的诊断及骨骼肌损伤的鉴别诊断中得到了广泛应用。目前正逐渐取代包括CK-MB在内的其它血清酶检测指标而成为判断心肌损伤,特别是诊断急性心肌梗死(Acute Myocardial Infarction.AMI)的"金标准"。同时心肌肌钙蛋白I对心肌疾病的病情监测、疗效观察及预后评估都具有较高的临床应用价值。本文对cTnI的国内外临床应用研究进展进行综述。     

急性肺栓塞患者血浆肌钙蛋白I对预后的评估价值

目的 探讨血浆肌钙蛋白I(ScTnI)对急性肺动脉血栓栓塞(PTE)预后的评估价值.方法 将我院2009年1月～2012年12月确诊为急性PTE并行ScTnI检查的43例患者分为A组(ScTnI<0.03 ng/ml组)24例,B组(ScTnI≥0.03 ng/ml组)19例,分析ScTnI水平与预后的关系.结果 ScTnI水平升高与大面积肺栓塞、低血压休克、死亡相关(r分别为0.477、0.616、0.617,P<0.05).结论 ScTnI水平可作为肺栓塞危险分层及评估预后的重要指标.     

CMOS-compatible, label-free silicon-nanowire biosensors to detect cardiac troponin I for acute myocardial infarction diagnosis

A label-free biosensor for electrical detection of cardiac troponin I (cTnI), a highly sensitive and selective biomarker of acute myocardial infarction (AMI), is demonstrated using silicon nanowire (SiNW) based field-effect transistors (FETs). The FET devices were fabricated by a complementary metal oxide semiconductor (CMOS) compatible top-down approach to define the SiNW followed by tetramethylammonium hydroxide (TMAH) wet etching. Electrical characterizations of the SiNW FET revealed an ambipolar conduction characteristic with an on/off ratio of 10(5)-10(6). CTnI monoclonal antibodies were then covalently immobilized on the SiNW surfaces. By integrating with a homemade biosensor measurement system, the biosensor exhibited rapid and sensitive response to cTnI proteins. The current response showed a nature of logarithm relationship against the cTnI concentration from 46 ng/mL down to 0.092 ng/mL. Moreover, an anti-interference capability of the fabricated biosensor was also assessed. By utilizing the top-down fabrication method, this work provides an efficient way for the cTnI proteins detection with an enormous potential of mass-production, which definitely facilitate the practical applications.     

Alterations in serum selenium levels and their relation to troponin I in acute myocardial infarction

Selenium (Se) is an essential trace element with antioxidant function. The aim of the present study was to estimate the alterations of Se serum level during the acute phase of myocardial infarction and its relation to biomarkers of myocardial necrosis. Serum Se levels were measured at admission and after 24 h in 60 consecutive patients with acute coronary syndrome (both with and without ST elevation). Troponin I (TnI) was assessed at admission and then twice daily for 3 days; patients with normal levels were excluded. Fifty-five patients with acute MI (positive TnI) were included into the analysis. During the first day of hospitalization, patients received standard therapy, including acetylsalicylic acid, clopidogrel, and heparin or enoxaparin; all underwent urgent coronary angiography and percutaneous intervention, when appropriate. Mean Se levels at baseline and 24 h later were comparable (67.1 ± 2.1 vs. 67.2 ± 1.8 μg/L, ns). Linear regression has shown significant correlation between baseline Se levels and peak TnI (y = 3.4x ? 116, r ² = 0.13, P = 0.008). Positive correlation was found also between the peak TnI and the difference from baseline to 24 h (y = 2.2x + 115, r ² = 0.08, P = 0.04). Moreover, close negative correlation was observed between baseline Se levels and the difference from baseline to 24 h (y = ?0.9x + 62.7, r ² = 0.55, P<0.001). Our results have shown marked individual changes in Se levels during the acute phase of MI as well as correlation between Se levels and peak TnI. These results suggest that alterations in serum Se may be related to the extent of myocardial infarction.     

Identification of acute myocardial infarction in elderly patients using optimized highly sensitive troponin I thresholds

Purpose: Established diagnostic thresholds for high-sensitivity cardiac troponins (hs-cTn) might not apply for elderly patients as they are elevated irrespective of the presence of an acute myocardial infarction (AMI). Aim of the present study was to investigate hs-cTnI in elderly patients with suspected AMI and to calculate optimized diagnostic cutoffs.

Material and methods: Data from a prospective multi-centre study and from a second independent prospective single-centre cohort study were analysed. A number of 2903 patients were eligible for further analysis. Patients > 70 years were classified as elderly. hs-cTnI was measured upon admission.

Results: Around 34.7% of 2903 patients were classified as elderly. Around 22.5% of elderly patients were finally diagnosed with AMI. Elderly patients had higher hs-cTnI levels at admission irrespective of the final diagnosis (p?<?0.001). According to the AUROC, hs-cTnI was a strong marker for detection of AMI in elderly patients. Application of the 99th percentile cutoffs showed a substantially lower specificity in elderly. By using optimized thresholds, specificity was improved to levels as in younger patients in both cohorts but accompanied with a decrease in sensitivity.

Conclusions: hs-cTnI levels have a lower specificity for detecting AMI in elderly patients. This lower specificity can be improved by using hs-cTnI thresholds optimized for elderly patients.     

pH-responsive titratable inotropic performance of histidine-modified cardiac troponin I

Cardiac troponin I (cTnI) functions as the molecular switch of the thin filament. Studies have shown that a histidine button engineered into cTnI (cTnI A164H) specifically enhances inotropic function in the context of numerous pathophysiological challenges. To gain mechanistic insight into the basis of this finding, we analyzed histidine ionization states in vitro by studying the myofilament biophysics of amino acid substitutions that act as constitutive chemical mimetics of altered histidine ionization. We also assessed the role of histidine-modified cTnI in silico by means of molecular dynamics simulations. A functional in vitro analysis of myocytes at baseline (pH 7.4) indicated similar cellular contractile function and myofilament calcium sensitivity between myocytes expressing wild-type (WT) cTnI and cTnI A164H, whereas the A164R variant showed increased myofilament calcium sensitivity. Under acidic conditions, compared with WT myocytes, the myocytes expressing cTnI A164H maintained a contractile performance similar to that observed for the constitutively protonated cTnI A164R variant. Molecular dynamics simulations showed similar intermolecular atomic contacts between the WT and the deprotonated cTnI A164H variant. In contrast, simulations of protonated cTnI A164H showed various potential structural configurations, one of which included a salt bridge between His-164 of cTnI and Glu-19 of cTnC. This salt bridge was recapitulated in simulations of the cTnI A164R variant. These data suggest that differential histidine ionization may be necessary for cTnI A164H to act as a molecular sensor capable of modulating sarcomere performance in response to changes in the cytosolic milieu.     

Release kinetics of high-sensitivity cardiac troponins I and T and troponin T upstream open reading frame peptide (TnTuORF) in clinically induced acute myocardial infarction

Context: Troponin T upstream open reading frame peptide (TnTuORF) may be useful as a novel biomarker in acute cardiac syndromes.

Objective: The study examined the early release kinetics of TnTuORF.

Materials and methods: We analyzed the time course of the release of cardiac troponins I and T and TnTuORF in patients (n?=?31) with hypertrophic obstructive cardiomyopathy undergoing transcoronary ablation of septal hypertrophy (TASH).

Results: Fifteen minutes after TASH, the levels of both troponins increased significantly (cTnT median: 18?ng/L versus 27?ng/L; cTnI median: 15?ng/L versus 25?ng/L). TnTuORF showed no variation.

Discussion: We observed a significantly greater increase in cTnI compared with cTnT.

Conclusion: Our results demonstrate that troponin assays allow early detection of myocardial injury, whereas TnTuORF levels remain unchanged in this setting.     

Modulation of cardiac troponin C-cardiac troponin I regulatory interactions by the amino-terminus of cardiac troponin I

Multidimensional heteronuclear magnetic resonance studies of the cardiac troponin C/troponin I(1-80)/troponin I(129-166) complex demonstrated that cardiac troponin I(129-166), corresponding to the adjacent inhibitory and regulatory regions, interacts with and induces an opening of the cardiac troponin C regulatory domain. Chemical shift perturbation mapping and (15)N transverse relaxation rates for intact cardiac troponin C bound to either cardiac troponin I(1-80)/troponin I(129-166) or troponin I(1-167) suggested that troponin I residues 81-128 do not interact strongly with troponin C but likely serve to modulate the interaction of troponin I(129-166) with the cardiac troponin C regulatory domain. Chemical shift perturbations due to troponin I(129-166) binding the cardiac troponin C/troponin I(1-80) complex correlate with partial opening of the cardiac troponin C regulatory domain previously demonstrated by distance measurements using fluorescence methodologies. Fluorescence emission from cardiac troponin C(F20W/N51C)(AEDANS) complexed to cardiac troponin I(1-80) was used to monitor binding of cardiac troponin I(129-166) to the regulatory domain of cardiac troponin C. The apparent K(d) for cardiac troponin I(129-166) binding to cardiac troponin C/troponin I(1-80) was 43.3 +/- 3.2 microM. After bisphosphorylation of cardiac troponin I(1-80) the apparent K(d) increased to 59.1 +/- 1.3 microM. Thus, phosphorylation of the cardiac-specific N-terminus of troponin I reduces the apparent binding affinity of the regulatory domain of cardiac troponin C for cardiac troponin I(129-166) and provides further evidence for beta-adrenergic modulation of troponin Ca(2+) sensitivity through a direct interaction between the cardiac-specific amino-terminus of troponin I and the cardiac troponin C regulatory domain.     

The potential of optimizing prehospital triage of patients with suspected acute myocardial infarction using high-sensitivity cardiac troponin T and copeptin

Purpose: In patients with a suspected acute myocardial infarction (AMI), to evaluate the potential for early triage based on measurement of high-sensitivity cardiac troponin T (hs-cTnT) and copeptin in blood samples collected in the prehospital phase.

Materials and methods: In this retrospective study, we measured hs-cTnT and copeptin in blood samples collected in the ambulance form 962 patients with suspected AMI. The diagnostic accuracy was estimated by receiver-operating characteristic (ROC) curve area under the curve (AUC) for both biomarkers and a combined model. Multivariable Cox regression modelling was used to estimate the predictive value of both biomarkers.

Results: In total, 178 (19%) cases had AMI. The AUC for hs-cTnT was 0.81. Adding copeptin increased the AUC to 0.85 (p?=?0.004) and the combined model allowed a prehospital rule-out of 45% of cases without AMI (negative predictive value, NPV 98%). Both biomarkers are highly predictive of outcome.

Conclusions: A future application of hs-cTnT and copeptin measurement, performed already in the prehospital phase, could potentially improve the prehospital diagnostic and prognostic classification of patients with a suspected AMI.     

Effects of G-CSF on cardiac remodeling after acute myocardial infarction in swine

We examined whether granulocyte colony-stimulating factor (G-CSF) prevents cardiac dysfunction and remodeling after myocardial infarction (MI) in large animals. MI was produced by ligation of left anterior descending coronary artery in swine. G-CSF (10 microg/kg/day, once a day) was injected subcutaneously from 24h after ligation for 7 days. Echocardiographic examination revealed that the G-CSF treatment induced improvement of cardiac function and attenuation of cardiac remodeling at 4 weeks after MI. In the ischemic region, the number of apoptotic endothelial cells was smaller and the number of vessels was larger in the G-CSF treatment group than in control group. Moreover, vascular endothelial growth factor was more abundantly expressed and Akt was more strongly activated in the ischemic region of the G-CSF treatment group than of control group. These findings suggest that G-CSF prevents cardiac dysfunction and remodeling after MI in large animals.     

Prospective validation of a 1-hour algorithm to rule-out and rule-in acute myocardial infarction using a high-sensitivity cardiac troponin T assay

Background:We aimed to prospectively validate a novel 1-hour algorithm using high-sensitivity cardiac troponin T measurement for early rule-out and rule-in of acute myocardial infarction (MI).Methods:In a multicentre study, we enrolled 1320 patients presenting to the emergency department with suspected acute MI. The high-sensitivity cardiac troponin T 1-hour algorithm, incorporating baseline values as well as absolute changes within the first hour, was validated against the final diagnosis. The final diagnosis was then adjudicated by 2 independent cardiologists using all available information, including coronary angiography, echocardiography, follow-up data and serial measurements of high-sensitivity cardiac troponin T levels.Results:Acute MI was the final diagnosis in 17.3% of patients. With application of the high-sensitivity cardiac troponin T 1-hour algorithm, 786 (59.5%) patients were classified as “rule-out,” 216 (16.4%) were classified as “rule-in” and 318 (24.1%) were classified to the “observational zone.” The sensitivity and the negative predictive value for acute MI in the rule-out zone were 99.6% (95% confidence interval [CI] 97.6%–99.9%) and 99.9% (95% CI 99.3%–100%), respectively. The specificity and the positive predictive value for acute MI in the rule-in zone were 95.7% (95% CI 94.3%–96.8%) and 78.2% (95% CI 72.1%–83.6%), respectively. The 1-hour algorithm provided higher negative and positive predictive values than the standard interpretation of highsensitivity cardiac troponin T using a single cut-off level (both p < 0.05). Cumulative 30-day mortality was 0.0%, 1.6% and 1.9% in patients classified in the rule-out, observational and rule-in groups, respectively (p = 0.001).Interpretation:This rapid strategy incorporating high-sensitivity cardiac troponin T baseline values and absolute changes within the first hour substantially accelerated the management of suspected acute MI by allowing safe rule-out as well as accurate rule-in of acute MI in 3 out of 4 patients. Trial registration: ClinicalTrials.gov, {"type":"clinical-trial","attrs":{"text":"NCT00470587","term_id":"NCT00470587"}}NCT00470587Acute myocardial infarction (MI) is a major cause of death and disability worldwide. As highly effective treatments are available, early and accurate detection of acute MI is crucial.^1–5 Clinical assessment, 12-lead electrocardiography (ECG) and measurement of cardiac troponin levels form the pillars for the early diagnosis of acute MI in the emergency department. Major advances have recently been achieved by the development of more sensitive cardiac troponin assays.^6–15 High-sensitivity cardiac troponin assays, which allow measurement of even low concentrations of cardiac troponin with high precision, have been shown to largely overcome the sensitivity deficit of conventional cardiac troponin assays within the first hours of presentation in the diagnosis of acute MI.^6–15 These studies have consistently shown that the classic diagnostic interpretation of cardiac troponin as a dichotomous variable (troponin-negative and troponin-positive) no longer seems appropriate, because the positive predictive value for acute MI of being troponin-positive was only about 50%.^6–15 The best way to interpret and clinically use high-sensitivity cardiac troponin levels in the early diagnosis of acute MI is still debated.^3,5,7In a pilot study, a novel high-sensitivity cardiac troponin T 1-hour algorithm was shown to allow accurate rule-out and rule-in of acute MI within 1 hour in up to 75% of patients.¹¹ This algorithm is based on 2 concepts. First, high-sensitivity cardiac troponin T is interpreted as a quantitative variable where the proportion of patients who have acute MI increases with increasing concentrations of cardiac troponin T.^6–15 Second, early absolute changes in the concentrations within 1 hour provide incremental diagnostic information when added to baseline levels, with the combination acting as a reliable surrogate for late concentrations at 3 or 6 hours.^6–15 However, many experts remained skeptical regarding the safety of the high-sensitivity cardiac troponin T 1-hour algorithm and its wider applicability.¹⁶ Accordingly, this novel diagnostic concept has not been adopted clinically to date. Because the clinical application of this algorithm would represent a profound change in clinical practice, prospective validation in a large cohort is mandatory before it can be considered for routine clinical use. The aim of this multicentre study was to prospectively validate the high-sensitivity cardiac troponin T 1-hour algorithm in a large independent cohort.